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Leiomyosarcoma (LMS) of soft-tissue origin was studied on the expression and the
biological significance of apoptosis in relation to p53 oncoprotein.  Immunohistochemical
analysis was performed initially on the paraffin-embbeded sections taken from 29
surgical tissues (20 cases) including 9 recurrent/metastatic tumors.  The results are as
follows:  A positive correlation was observed between the p53 indices (PIs) and the
proliferative markers designated by Ki-67, PCNA and MCM2, both of which increased
significantly in the high-grade malignant LMS much more than in the low-grade one
(P < 0.001).  Apoptotic cells were detected by the TUNEL method and evaluated as the
apoptotic index (AI).  A high AI-level was shown in the high-grade malignant LMS,
especially in cases of the recurrent/metastatic sites in comparison with the tumors of
the primary site (P < 0.05).  The AI was statistically higher in the p53-positive cases of
high-grade malignant LMS than in the p53-negative cases of low-grade malignant LMS.
In conclusion, apoptotic activity paralleled the overexpression of p53 protein along
with an increasing grade of malignancy and may be related intimately to the increased
malignant potential, especially to recurrence/metastasis.
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Leiomyosarcoma (LMS) is now known as one
of the most frequent malignant tumors occur-
ring in the soft-tissue of adults. It has been di-
vided into 3 categories according to location by
Enzinger and Weiss (1988), because of its clini-
cal and biological behavior.  Hashimoto et al.
(1986) emphasized a prognostic difference be-
tween superficial and deep forms of LMS, an
adverse prognosis of the deep form as compar-
ed to the superficial form.  Histologically, con-
ventional LMS is classified currently into well,
moderately and poorly/anaplastic differentiated
types depending on the degree of differentia-
tion, but it is very difficult to evaluate the ma-
lignancy in predicting metastasis despite the
multiple factors of size, cellularity, atypia and
necrosis which are known as prognostic factors.
Even at the level of mitotic activity, a serious
decision can hardly be made on the biological
behavior of LMS (Enzinger and Weiss, 1988).
Apoptosis is an active process of cell death
occurring in both normal and neoplastic condi-
tions and is characterized as the orderly parti-
cipation of biological, morphological and mo-
lecular genetic events (Kerr et al., 1972, 1994;
Wyllie, 1981; Umansky, 1982).  It is induced by
a variety of agents including oncogenic pro-
teins, mainly p53 protein, the bcl-2 gene family
and Fas/Fas legand among the process and re-
gulation of apoptosis (Kerr et al., 1994).  Recent
studies have disclosed 2 pathways for the ex-
pression of apoptosis (Clarke and Purdie, 1993;
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Endo et al., 1999):  p53 gene-dependent (Haupt
et al., 1966; Chen et al., 1996) and -independent
pathways, the latter of which can be induced by
growth factors, hormones, chemotherapeutic
agents and radiation (Clarke and Purdie, 1993;
Endo et al., 1999).  In considering malignant
neoplasma, apoptosis may play an important
role in the regulation of tumor growth in
intimate relation to the p53 gene regulating the
cell cycle in conjunction with cell proliferation.
The relationship between p53 gene status and
apoptosis, however, has rarely been reported on
soft-tissue sarcoma (Staunton and Gaffney, 1995;
Yuki et al., 1995; Nakanishi et al., 1997; Valenti et
al., 1998).  We examined the relationship between
the p53 protein and apoptosis in 29 surgical
specimens from 20 cases of LMS of soft-tissue
origin which were classified histologically from
low-grade to high-grade malignancies according
to the mitotic rate and proliferative cell markers.
In addition, we discussed the significance and
evaluation of apoptotic activity as a biological and
prognostic factor of LMS.
Materials and Methods
This study was performed on 29 paraffin-
embedded tumor tissues from 20 cases of LMS
of soft-tissue origin, all of which were removed
surgically.  The histological diagnosis of these
cases were determined in addition to immuno-
histochemical findings of vimentin, alpha-
smooth muscle actin and HHF 35, and classifi-
ed into 3 groups according to tumor cell differ-
entiation from poorly to well differentiated
types.  Mitotic activity is an another aid in eval-
uating tumor malignancy and thus, the number
of mitoses was counted in 10 high-power fields
selected randomly as a mitotic rate: under 10 as
low-grade, 10 to 20 as intermediate and over 20
as high-grade malignancies.
The clinical data for these cases were col-
lected from medical records.  Each case in this
study was analyzed according to the tumor
nodes metastases classification developed by
the Union Internationale Contra le Cancer to
evaluate the relation of apoptotic activity in
LMS to their biological behavior.
Immunohistochemistry
An immunohistochemical study was performed
by the streptavidin-biotin-complex method us-
ing the following monoclonal antibodies:  anti-
p53 nuclear protein (DO-7, 1:50, Dako, Glostrup,
Denmark), anti-Ki-67 (MIB-1, 1;50, Immunotech,
Marceille, France), anti-proliferating cell nu-
clear antigen (PCNA) (PC10, Nichirei, Tokyo,
Japan) and anti-minimichrosome maintenance
2 protein (MCM2).  MCM proteins are com-
posed of 6 isoforms ranging from MCM2 to
MCM7.  They are expressed in the G1/S phase
of the cell cycle and bind to DNA strands for a
replication of DNA under the presence of DNA
polymerase.  Monoclonal antibody (2H10 clone)
against MCM2 protein was produced by the im-
munization of oligopeptide of N-terminal from
MCM2 protein with 892 amino acids and was
reported as a proliferative marker available to
examine the grading of malignancy*.  The de-
paraffinized sections were pretreated with cit-
rate buffer (0.01 mol/L citric acid:  pH 6.0) at
92˚C for 30 min in a microwave oven (Azumaya
MI-77, Osaka, Japan) for all antibodies except
anti-PCNA antibody and then incubated at 4˚C
overnight with the primary antibodies.  The
positive cells were counted and evaluated as the
ratio of immunoreactive cells to the total num-
ber of 1,000 tumor cells.
TUNEL
Terminal deoxynucleotidyl transferase-medi-
ated dUTP-biotin nick end labeling (TUNEL)
was employed for the detection of apoptotic
cells using an ApopTag Plus in situ apoptosis
detection kit (Oncor, Gaithersburg, MD) which
was followed by the method originally devel-
oped by Kerr et al. (1972).  Briefly, the sections
were incubated with 20 µg/mL proteinase K
(Behringer Mannheim/Yamanouchi, Tokyo)
for 15 min at 37˚C after blocking endogenous
peroxidase in methanol for 30 min at room tem-
perature.  Thereafter, the sections were layered
and incubated on terminal deoxynucleotidyl
transferase with digoxigenin-11-dUTP in a
*Shomori K.  Personal communication.
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moist chamber for 90 min at 37˚C.  After
stopping the reaction, anti-digoxigenin-
peroxidase was applied to the reaction mixture
for 30 min at room temperature.  The positive
reaction was estimated with 3,3'-diamino-
benzidine reaction at room temperature.  The
positive cells were counted and evaluated as the
ratio of TUNEL-positive cells to a total number
of more than 1,000 tumor cells.
Results
The clinicopathologic data are shown in Table
1.  The patients were comprised of 7 males and
13 females. The age distribution was from 35 to
76 years old (mean age, 65.6 years).  The pri-
mary sites of the tumors involved 12 from the
retroperitoneum and abdomen, 4 from the lower
extremities, 1 from the upper extremity and 1
from the trunk in addition to 1 from the uterus.
Recurrent/metastatic cases were included in 4
cases (10 specimens).  Twenty nine specimens
from 20 cases of LMS of soft-tissue origin were
histologically evaluated into 3 categories of
malignancy based on tumor cell differentiation
and the mitotic index:  9 low-grade, 8 inter-
mediate and 12 highly malignant LMSs (Table
2).  The cases of low-grade malignancy appear-
ed very clear in cell differentiation showing less
than 10 mitotic figures per 10 high-power fields
selected randomly.  The cases of intermediate
malignancy were well to moderate in cell dif-
ferentiation associated with 10 to 20 mitotic
figures, and in high-grade malignancy, the tu-
mor cells were poorly differentiated assuming
Table 1.  Clinical data of the cases used in
this study
Age range (mean)* 35–76 (65.6)
Sex ratio (male:female)   7:13
Primary site
     Retroperitoneum and abdomen    11
     Upper extremity      1
     Lower extremity      4
     Body      1
     Uterus      1
Recurrence/metastasis      5
*year.
Table 2.  Comparative studies on LMS categorized in 3 groups according to the mitotic rate
  Malignancy Number Cell AI PI Cell proliferation
of differ-
specimens entiation Ki-67 PCNA MCM2
Low-grade     (< 10) 9 Well 0.4 ± 0.2   0.4 ±  1.8   2.0 ± 0.6   6.8 ± 1.2   3.2 ±  0.8
Intermediate (10–20) 8 Moderately 1.2 ± 0.5   4.6 ±  2.7   5.0 ± 3.2 16.9 ± 2.6   9.7 ±  2.1
High-grade     (20 <) 12 Poorly 1.3 ± 0.9 23.7 ±15.0 16.7 ± 5.0 33.4 ± 6.8 22.1 ±10.7
Mean ± SD.
(  ), mitotic rate/10 high-power field.
AI, apoptotic index; LMS, leiomyosarcoma; MCM2, minimichrosome 2; PCNA, proliferating cell nuclear antigen;
PI, p53 index; TUNEL, terminal deoxynuleotidyl transferase-mediated dUTP-biotin nick end labeling.
pleomorphic giant cells abundantly.  The mitot-
ic figures were easily encountered at a ratio of
over 20 per 10 high-power fields (Figs. 1a–d).
TUNEL labeling for apoptotic cells
Apoptotic cells were determined by the TUNEL
method and evaluated as the apoptotic index
(AI).  Apoptotic cells were distinguished as
cells with condensed and fragmented nuclei
separated by a clear halo in hematoxylin and
eosin stain (Fig. 1d).  TUNEL-positivity was
observed at a varying degree to the cell nuclei
with condensed and fragmented nuclei and oc-
casionally to tumor cells which looked normal
(Figs. 2a and b).  Table 2 shows the AI, posi-
tivities of p53 and the proliferative markers (Ki-
67, PCNA and MCM2) of LMS categorized
into 3 groups according to the mitotic rate.  The
immunohistochemical findings of p53 as well
as Ki-67, PCNA and MCM2 are shown in Figs.
2c and d.  Nine low-grade malignant LMSs
showed 0.4 ± 0.2 of AI (mean ± SD) and 0.4 ±
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Fig. 1. Histological findings of LMS.  Hematoxylin and eosin stain, × 200.
a: Well-differentiated LMS; mitotic cells, 9/10 HPF, low-grade malignancy, 71/F.
b: Moderately-differentiated LMS; mitotic cells, 10/10 HPF, intermediate malignancy, 76/F.
c: Poorly-differentiated LMS; mitotic cells, 34/10 HPF, high-grade malignancy, 63/F.
d: Arrow indicates an apoptotic cell.
1-a 1-b
1-d1-c
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Figs. 2a and b.  TUNEL for apoptotic cells.  Positive for the tumor cell nuclei at a varying degree.  a:  AI = 5.1;
third-recurrent tumor, 63/F.  b:  AI = 0.8; poorly-differentiated LMS, primary, 61/F.
Fig. 2c.  Immunohistochemical stain of p53 protein.  Strongly positive for the tumor cell nuclei.  PI = 57,
poorly-differentiated LMS, 74/F.
Fg. 2d.  Immunohistochemical stain of Ki-67.  Positive for the tumor cell nuclei at a various degree; 21.5%,
poorly-differentiated LMS, 74/F.
2-a 2-b
2-d2-c
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0.18 of PI, whereas 12 high-malignant LMSs
were statistically higher at a rate of 1.1 ± 0.9
and 23.9 ± 15.0, respectively (P < 0.05).  Three
kinds of proliferative markers of Ki-67, PCNA
and MCM2 proteins were examined to assess
the proliferating activity of the tumor cells di-
vided into 3 categories of malignancy.  The nu-
clear positivities of Ki-67, PCNA and MCM2
increased statistically in the high-grade malig-
nant LMSs at a rate of 16.7 ± 6.8 in Ki-67, 33.4
± 6.8 in PCNA and 22.1 ± 10.7 in MCM2, more
than those of the low-grade ones, respectively
(2.0 ± 0.6 in Ki-67, 6.8 ± 1.2 in PCNA and 3.2 ±
0.8 in MCM2).
Relationship between TUNEL indices
and p53 expression
TUNEL and p53 positivities were examined
comparatively in primary LMSs (3 cases) and
their recurrent/metastatic tumors (9 tumors) as
shown in Table 3.  TUNEL indices (AIs) of the
recurrent/metastatic tumors were statistically
higher (mean AI:  2.0 ± 0.7) in comparison with
the primary site (0.4 ± 0.1).  p53-positive cells
increased significantly in cases of the recurrent/
metastatic tumors (mean PI:  12.3 ± 3.1) than in
those of the primary tumors (0.6 ± 0.5) (P < 0.05)
in the same way.
Expression of apoptotic cells between
p53-positive and -negative LMSs
Low-grade malignant LMS showed a rate of PI
under 5 as shown in Table 2, and thus we figur-
ed that p53-positive tumors were rated over 5
PI.  The p53-positive LMSs were found in 12 of
29 tumors as shown in Table 4 and revealed the
AI at a mean of 2.2 ± 1.6, statistically higher
than that (0.4 ± 0.1) of the p53-negative LMSs
(P < 0.05).  Histologically, the p53-positive
group included 8 (66.7%) of 12 high-grade and
4 (50%) of 8 intermediate malignancies, where-
as 9 (100%) low-grade and 4 (50%) of 8 interme-
diate malignant LMSs were included in the p53-
negative group.  The recurrence/metastasis-free
Table 4.  AI between p53-negative and positive cases in 3 histological groups
PI Number AI Histological grading
of
specimens Low Intermediate High
p53-negative < 5 17 0.4 ± 0.1  9 [1] 4 [2] 4
p53-positive 5 ≤ 12 1.5 ± 0.8  0 4 [3] 8 [3]
Mean ± SD.
[  ], number of recurrent/metastatic cases.
AI, apoptotic index; PI, p53 index.
Table 3.  Comparative study on immunohistochemistry by the TUNEL method between 3
primary tumors and their recurrent/metastatic tumors
Histological Number AI PI Cell proliferation
grading of
mitoses Ki-67 PCNA MCM2
Primary tumor  [3] Low   2–  9 0.4 ± 0.1   0.6 ± 0.5   0.5 ± 0.2   8.4 ± 2.4   3.8 ± 2.7
Recurrent/meta- Intermediate-
   static tumor* [9] high 11–34 2.0 ± 0.7 12.3 ± 3.1 12.8 ± 3.5 22.1 ± 9.6 18.1 ± 7.9
Mean ± SD.
[  ], number of specimens.
* Recurrent period:  2–7 years.
AI, apoptotic index; MCM2, minimichrosome 2; PCNA, proliferating cell nuclear antigen; PI, p53 index;
TUNEL, terminal deoxynuleotidyl transferase-mediated dUTP-biotin nick end labeling.
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survival rate was compared between the p53-
positive and -negative groups (Fig. 3).  The pa-
tients with p53-positive tumors was significant-
ly worse than those with p53-negative tumors
(log-rank test: P = 0.047).
Discussion
In this study, we evaluated the frequency of
apoptotic cell death in an increasing malignant
potential of LMS based on mitotic rate as well
as expression of the proliferative markers of Ki-
67/PCNA/MCM2 responsible of tumor growth.
Secondly, the relationship between p53 over-
expression and AIs was investigated to clarify
the significance of apoptosis on tumor malig-
nancy and prognostic factor.  Our results show-
ed a positive correlation between mitotic rate
and increasing grade of histological malignancy
on the one hand and the proliferative markers of
Ki-67/PCNA/MCM2 on the other.  These find-
ings were exactly similar to those reported be-
fore by others (Drobijak et al., 1994; Yoo et al.,
1997; Konomoto et al., 1998).  MCM2 protein
is part of the MCM family which is composed
of 6 isoforms of MCM2 to MCM7.  They are
expressed in the G1/S phase of the cell cycle
and bind to DNA strands for replication of
DNA under the existence of DNA polymerase.
The positivity for anti-MCM2 antibody ranged
between those of Ki-67 and PCNA.
We observed p53 positivity in 12 (41.4%) of
29 LMSs, of which histological grading was
high-malignant in 8 and intermediate malignant
in 4.  In the current study, p53-immunostaining
was positive at a rate of 20 to 64% in various
types of soft-tissue sarcomas (Yoo et al, 1997;
Stefanou et al, 1998) and 21.6 to 43% of LMS
of soft-tissue origin (O’Reilly et al., 1997;
Konomoto et al., 1998).  The mutated p53 gene
loses its inherent transcriptional activity, result-
ing in enhancement of tumor cell proliferation
(Endo et al., 1999).  Yoo et al. (1997) suggested
the role of the p53 mutation as the pathogenesis
of soft-tissue sarcomas.  Regarding the biolog-
ical behavior or prognostic factor, however, the
overexpression of p53 protein was estimated as
being diverse from the one suggesting a posi-
tive correlation between p53 protein and prog-
nosis (Drobijak et al., 1994; Toffoli et al., 1994;
Yoo et al., 1997) to the others that indicated no
relation between p53 expression and biological
behavior (O’Reilly et al., 1997; Stefanou et al.,
1998).  We would like to emphasize here that
the overexpression of p53 protein could be
highly valuable as a prognostic
factor taken from the findings of an
increasing accumulation of p53
protein with an intimate relation to
the grading of tumor malignancy.
Detection and identification of
apoptotic cells was successfully car-
ried out on the paraffin-embedded
sections by using the TUNEL meth-
od which was introduced and devel-
oped by Gavrieli et al. (1992) and
Leoncini et al. (1993) and is based on
detecting naturally occurring DNA
strand breaks.  TUNEL-positive,
apoptotic cells were easily recog-
nized as the cells with nuclear con-
densation, fragmentation separated
by a clear halo around the cells in
hematoxylin and eosin staining, in
addition to the number of normal-
looking cells as mentioned previ-
Fig. 3.  Recurrence/metastasis-free survival curves of patients
with p53-positive and -negative leiomyosarcoma (LMS).  Patients
with p53-positive tumors were significantly worse than those with
p53-negative tumors (log-rank test:  P = 0.047).  [  ], number of
specimens.
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ously by others (Lowe et al., 1994; Aihara et al.,
1994; Arai and Kino, 1995).
We compared AI and PI with histological
grading resulting in a positive correlation of AI
to PI which increased statistically from low-
grade to high-grade malignancy.  The AI value,
furthermore, was statistically much higher in
p53-positive cases of high-grade malignant
LMS than in p53-negative cases.  Thus, in cases
of high-grade malignant LMS, especially recur-
rent/metastatic tumors, a more rapid growth of
tumors caused by increased proliferative activ-
ity was probably due to a loss of regulation by
p53.  Apoptosis is regulated and controlled in
its expression by various oncogens and sup-
presser genes (Kerr and Hormon, 1994).  p53
gene is one of the major regulators of apoptosis
which can easily allow apoptosis in association
with MDM2 by regulating the cell cycle in the
manner of growth arrest at G1/S or G2/S phase
or apoptotic cell death, but the mutative p53
gene suppresses apoptosis by a loss of tran-
scriptional activity to cyclin-dependent kinase
(Aihara et al., 1994).  Ikeda et al. (1998) de-
monstrated that naturally occurring apoptosis
appeared to be induced predominantly via a
p53-independent pathway from the observa-
tion of early and advanced gastric carcinoma.
Kawauchi et al. (2000) suggested that apoptosis
in cases of synovial sarcoma may be thought to
be caused by a multiple apoptosis-regulating
mechanism other than p53 protein.  Our find-
ings of a positive correlation between an in-
creased amount of apoptotic cells and p53 posi-
tivity, however, is most likely to indicate that
apoptotic status was induced via a p53-depen-
dent pathway.
There has been a positive correlation re-
ported between apoptotic cells and higher
malignancies of non-Hodgkin’s lymphomas
(Leoncini et al., 1993), prostatic carcinomas
(Aihara et al, 1994) and colorectal adenomas
(Arai and Kino, 1995).  Tatebe et al. (1996) also
reported that apoptosis and cell proliferation
were more frequent in metastatic foci than in
primary lesions of colorectal carcinoma and
suggested that apoptosis might reflect not only
cell loss, but proliferative activity.  A recent
study on synovial sarcoma indicated that apo-
ptosis may be an indicator of poor prognosis
(Kawauchi et al., 2000).  Our results support
this hypothesis from the comparative exami-
nation of primary tumors and their recurrent/
metastatic tumors.  We used the materials of
LMS originating in deep soft-tissue except for
one from organ-specific LMS of the uterus and
intestine which represented rather low mitotic
activity.  In fact, it is suggested that the suscep-
tibility of undergoing apoptosis may reflect the
histological differences between tumor types
(Staunton et al., 1995).  Therefore, the mecha-
nism and role of apoptosis in LMS still remain
to be elucidated.
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